What is your approach to continuing or altering therapy when inheriting a patient with combined biologic immunosuppression that is in excess of guidelines?

How do you approach de-escalation or justify therapy maintenance? Do you have tiers of medications that you attempt to de-escalate first? In one particular case, a patient has Rinvoq, Humira, Actemra, and ibrutinib for a combination of multiple autoimmune and autoinflammatory diagnoses.

Answer from: at Community Practice

This is by far the hardest task assigned for a practicing rheumatologist. Inheriting a patient on a regimen you did not develop and are uncomfortable continuing poses a daunting challenge: you are challenging the patient’s relationship with the previous rheumatologist, the control of the patie...

Comments

at UTMB Health
I agree with Dr. @DeMarco. It reminds me of a pati...

Please select the option that best describes you:

What is your approach to continuing or altering therapy when inheriting a patient with combined biologic immunosuppression that is in excess of guidelines?

Related Questions